Clinical Trial Update: Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing immunogenicity of a recombinant HPV nonavalent vaccine against Gardasil 9 in healthy women aged 18-26 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Condylomata Acuminata

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)
• HPV nonavalent vaccine (types 6,11,16,18,31,33,45,52,58) produced in E. coli (recombinant HPV nonavalent vaccine)

Snippet

Sponsor: Xiamen University | Conditions: Cervical Cancer, Condylomata Acuminata | Phase 3 | Status: COMPLETED